Sundry Photography/iStock Editorial via Getty Images
Axonics (NASDAQ:AXNX) ticked up 0.2% after Boston Scientific (NYSE:BSX) earlier reiterated that it sees a first half close of this year for its planned $3.7 billion acquisition.
Boston Scientific (BSX) expects the Axonics deal to “close first half of the year, so no change there,” Jonathan Monson, senior VP of investor relations, said earlier at a TD Cowen healthcare conference.
The comments come as the parties likely made HSR filings for the transaction in late January and the initial review for the deal should have been completed by last week, though the companies haven’t made any regulatory filings yet.
Axonics (AXNX) shares ticked down 0.8% on Thursday after Axonics (AXNX) said Medtronic (MDT) filed a complaint with the U.S. International Trade Commission and the U.S. District Court in Delaware alleging the company has infringed upon two Medtronic implantable device patents.
Boston Scientific (BSX) agreed to buy to acquire the med-tech firm for $71 per share in cash in January. The deal is expected to complete in the first half of 2024.